+

WO1995006649A1 - Macrolides antagonistes des immunosuppresseurs fixant la macrophiline - Google Patents

Macrolides antagonistes des immunosuppresseurs fixant la macrophiline Download PDF

Info

Publication number
WO1995006649A1
WO1995006649A1 PCT/EP1994/002894 EP9402894W WO9506649A1 WO 1995006649 A1 WO1995006649 A1 WO 1995006649A1 EP 9402894 W EP9402894 W EP 9402894W WO 9506649 A1 WO9506649 A1 WO 9506649A1
Authority
WO
WIPO (PCT)
Prior art keywords
macrolide
treating
alkyl
preventing
macrolides
Prior art date
Application number
PCT/EP1994/002894
Other languages
English (en)
Inventor
Theodor Fehr
Jean-Jacques Sanglier
Original Assignee
Sandoz Ltd.
Sandoz-Patent-Gmbh
Sandoz-Erfindungen Verwaltungsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd., Sandoz-Patent-Gmbh, Sandoz-Erfindungen Verwaltungsgesellschaft Mbh filed Critical Sandoz Ltd.
Priority to AU76925/94A priority Critical patent/AU7692594A/en
Publication of WO1995006649A1 publication Critical patent/WO1995006649A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/29—Micromonospora

Definitions

  • This invention relates to certain novel macrolides which are antagonists of macrophilin binding immunosuppressants, such as FK506 and rapamycin.
  • Rapamycin (sirolimus) is a macrolide antibiotic that is produced by Streptomyces hvgroscopicus. The structure of rapamycin is given, e.g., in McAlpine et al. (1991) J. Antibiotics 44: 688 and Schreiber et al. (1991) J. Am. Chem. Soc. 113: 7433. Rapamycin is an extremely potent immunosuppressant and also has anti-tumor and anti-fungal activity. However the utility of rapamycin as a pharmaceutical is restricted by its low and variable bioavailability and its high toxicity.
  • FK506 (tacrolimus) is a macrolide antibiotic that is produced by Streptomvces tsukubaensis No 9993. The structure of FK506 is given, e.g., in Tanaka et al. (1987) /. Am. Chem. Soc. 109: 5031. FK506 also is a potent immunosuppressant. FK506, however, is also toxic, particularly to the nervous system.
  • FK506 and rapamycin are believed to have somewhat different mechanisms of inducing immunosuppression; however, both bind strongly to macrophilins and suppress lymphocyte proliferation.
  • This invention provides novel macrolides having a novel profile of biological activity. Although the compounds bind strongly to macrophilins and inhibit adhesion molecule expression and epithelial cell proliferation, they do not suppress lymphocyte proliferation. These novel macrolides are useful as pharmaceuticals, e.g., as inhibitors of adhesion molecule expression, as antidotes to macrophilin binding immunosuppressants of the FK506 or rapamycin type, as steroid potentiators, and as Mip inhibitors, as well as in diagnostic and screening assays.
  • the novel macrolides are of formula I:
  • R is H, alkyl, aryl, or acyl
  • R 2 is H, or -OR 5 , such that R 5 is H, alkyl, aryl, or acyl;
  • R 3 is -CH 2 - or -CH 2 CH ;
  • R 4 is H, alkyl, acyl, or aryl.
  • alkyl refers to C,. 6 alkyl, e.g., methyl or ethyl
  • aryl refers to an aromatic hydrocarbon radical having one or two aromatic rings, e.g., phenyl or benzyl
  • acyl refers to alkylcarbonyl or arylcarbonyl (preferably a physiologically hydrolysable and acceptable acyl; that is, a residue which is cleavable under physiological conditions to yield an acid which is itself tolerated at the doses to be administered), e.g., acetyl, benzoyl, or salicyl.
  • the macrolides of the invention are those of formula Ia:
  • R is H or -CH 3 ;
  • R 2 is H or -OH; and
  • R 3 is -CH 2 - or -CH 2 CH 2 -.
  • Especially preferred compounds of formula Ia include the following:
  • the macrolides of formula I are shown to inhibit adhesion molecule expression.
  • Cellular adhesion molecules such as ICAM-1, VCAM-1 and E-selectin, are expressed on the surface of endothelial cells and keratinocytes in response to pro- inflammmatory mediators including TNF ⁇ , IFN ⁇ , ELI and LPS.
  • Corresponding counter- ligands e.g. LFA-1, VLA-4 and SLE"
  • Transendothelial migration of leucocytes during inflammatory processes as well as extravascular cell-cell interactions are regulated as a result of the interactions between these adhesion molecules and their counter-ligands. Consequently inhibitors of adhesion molecule expression offer potential for the treatment of many disease states. However, no suitable low molecular weight inhibitors of adhesion molecule expression are currently available.
  • the Macrolides are shown to inhibit VCAM, ICAM and ELAM expression in vitro at low micromolar or submicromolar levels. This activity can be confirmed in vivo; for example, a topical solution containing 1.2% of Compound B shows 39% inhibition of oxazolone induced allergic contact dermatitis compared to controls.
  • the compounds are useful for the treatment or prophylaxis of disease processes which involve expression of cellular adhesion molecules.
  • diseases/disorders where leucocyte trafficking plays a prominent role in the pathogenic process, most notably acute and chronic inflammation (e.g. allergy, asthma, psoriasis, reperfusion injury, rheumatoid arthritis and septic shock) and autoimmune states (e.g. multiple sclerosis).
  • Other indications for the compounds of the invention include tumour metastasis (e.g.
  • the compounds have therapeutic potential in hyperproliferative skin diseases (e.g. psoriasis) as well as various malignancies in view of their inhibitory activity at low micromolar concentrations when tested for 72 hours in a keratinocyte-based proliferation assay.
  • hyperproliferative skin diseases e.g. psoriasis
  • various malignancies in view of their inhibitory activity at low micromolar concentrations when tested for 72 hours in a keratinocyte-based proliferation assay.
  • the Macrolides are also potent macrophilin binders.
  • the macrophilin binding activity of the Macrolides can be shown using the macrophilin binding assay (MBA), which measures the ability of the Macrolides to compete with a macrophilin binding immunosuppressant for binding to a macrophilin.
  • MSA macrophilin binding assay
  • FK506, rapamycin, and immunosuppressive derivatives of these drugs are known to bind in vivo to macrophilin- 12 (also known as FK506 binding protein or FKBP-12), so the ability of the macrolide to compete with FK506 or rapamycin for binding to macrophilin- 12 can be measured.
  • FK506 is coupled to bovine serum albumin (BSA) and is then used to coat microtiter wells.
  • Biotinylated recombinant human macrophilin- 12 (biot-MAP) is allowed to bind in the presence or absence of the Macrolide to the immobilized FK506. After washing (to remove macrophilin- 12 which is not specifically bound to the immobilized FK506), the amount of bound biot-MAP is assessed by incubation with a streptavidin-alkaline phosphatase conjugate, followed by washing and subsequent addition of p-nitrophenyl phosphate as a substrate. The read-out is the OD at 405nm. Any binding of the Macrolide to the biot-MAP results in a decrease in the amount of biot-MAP that is bound to the FK506 and thus in a decrease in the OD 405.
  • the Macrolides e.g., Compounds A, B, C, and D, have an IC 50 of less than 10 nM in this assay, comparable to FK506 or rapamycin.
  • Macrolides have a substantially different mechanism of action from FK506 or rapamycin can be shown in standard in vitro assays in comparison to FK506 and rapamycin.
  • FK506 for example, is known to be a potent inhibitor of IL-2 transcription, as can be shown in an IL-2 reporter gene assay.
  • Rapamycin although not active in the IL-2 reporter gene assay, strongly inhibits IL-6 dependent T-cell proliferation. Both compounds are very potent inhibitors of the mixed lymphocyte reaction.
  • the Macrolides by contrast, are inactive in all of these assays.
  • Macrolides bind strongly to macrophilin without suppressing lymphocyte proliferation, they can be used in the treatment of overdoses of macrophilin-binding immunosuppressants, such as FK506 and rapamycin.
  • the Macrolides are particularly potent inhibitors of rapamycin activity.
  • Compounds B and C for example, completely abrogate the biological activity of rapamycin at approximately equimolar concentrations. To abrogate completely the biological activity of FK506, approximately a 100-fold molar excess is desirable.
  • the macrophilin binding activity of the Macrolides also makes them useful in enhancing or potentiating the action of corticosteroids.
  • MMTV-CAT murine mammary tumor virus-chloramphenicol acetyltransferase
  • Mip and Mip-like factors are virulence factors produced by a wide variety of pathogens, including those of the genera Chlamidia. e.g., Chlamidia trachomatis: Neisseria. e.g., Neisseria meningitidis; and Legionella. e.g., Legionella pneumophilia: and also by the obligately parasitic members of the order Rickettsiales. These factors play a critical role in the establishment of intracellular infection.
  • the efficacy of the Macrolides in reducing the infectivity of pathogens which produce Mip or Mip-like factors can be shown by comparing infectivity of the pathogens in cells culture in the presence and absence of the macrolides, e.g., using the methods described in Lundemose, et al., Mol. Microbiol. (1993) 7: 777.
  • this invention also provides the macrolides of formula I, e.g., of formula Ia, e.g., Compound A, B, C, or D, for use as a pharmaceutical, and pharmaceutical compositions comprising any of them, optionally in combination or association with a pharmaceutically acceptable diluent or carrier, e.g., for use in any of the following indications:
  • acute or chronic inflammation e.g. allergy, asthma, psoriasis, reperfusion injury, rheumatoid arthritis and septic shock
  • autoimmune autoimmune diseases e.g. multiple sclerosis
  • tumour metastasis e.g. melanoma, osteocarcinoma
  • immunosuppressants e.g., cyclosporin or FK506, and/or corticosteroids
  • hyperproliferative skin diseases e.g. psoriasis
  • various malignancies e.g. psoriasis
  • a macrophilin binding immunosuppressant e.g., FK506 or rapamycin
  • steroids e.g., for treating or preventing inflammation or for one of the other uses known for corticosteroids
  • infectious diseases e.g., prophylaxis or treatment of infections or infectuous diseases caused by organisms producing Mip or Mip-like factors (including organisms of the genera Chlamidia. e.g., Chlamidia trachomatis: Neisseria. e.g., Neisseria meningitidis: and Legionella. e.g., Legionella pneumophilia: and also the obligately parasitic members of the order Rickettsiales), optionally in combination with one or more other anti- infective agents.
  • infectious diseases e.g., prophylaxis or treatment of infections or infectuous diseases caused by organisms producing Mip or Mip-like factors (including organisms of the genera Chlamidia. e.g., Chlamidia trachomatis: Neisseria. e.g., Neisseria meningitidis: and Legionella. e.g., Legionella pneumophilia: and also the obligately parasitic members of
  • the invention also provides the use of a Macrolide in the manufacture of a medicament for use in any of these indications.
  • the invention also provides a method of treatment or prophylaxis of any of these indications, said method comprising administering a pharmaceutically effective amount of a Macrolide to a subject, e.g., a larger mammal, e.g., man, in need of such treatment.
  • the Macrolides may be produced synthetically, e.g., by total synthesis using a procedure analogous to that described for rapamycin by Nicolaou, et al., J. Am. Chem. Soc. (1993) 115: 4419, or by fermentation as described below, or by a combination of synthetic and biosynthetic means, e.g., by isolating fermentation products and further chemically modifying them.
  • the Macrolides are produced by fermentation using a microorganism of the genus Micromonospora. preferably the novel species of the genus Micromonospora designated A92-306401; for example, the strain which has been deposited by the applicant under the Budapest Convention on July 30, 1993 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Mascheroder Weg 1 B, D-38124 Braunschweig, Germany under accession number DSM 8429.
  • DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
  • Compounds A, B, C, and D may be obtained by cultivating the microorganism in an appropriate culture medium and then isolating the macrolide, e.g., by chromatography.
  • the invention therefore provides a process for the production of a macrolide, e.g., a macrolide of formula 1, e.g., of formula la, comprising cultivating a microorganism of the genus Micromonospora. e.g., of the species Micromonospora sp.A92-306401, e.g., of the deposited strain DSM 8429 in an appropriate culture medium and isolating the macrolide.
  • An appropriate culture medium is a medium containing suitable sources of nitrogen, carbon, and trace minerals.
  • the sources of carbon in the culture medium are carbohydrates such as glucose, xylose, galactose, glycerin, starch, and dextrin.
  • Preferred sources of nitrogen are yeast extract, meat extract, peptone, gluten meal, cottonseed meal, soybean meal, casein hydrolysates, soybean hydrolysates, yeast hydrolysates, and the like and inorganic and organic nitrogen-containing compounds such as ammonium salts, urea, amino acids and the like. Conventional fermentation agents and trace materials may also be added.
  • the invention also includes macrolides made using this fermentation process, including macrolides which are not within the scope of formula I.
  • the invention also includes the novel macrolide-producing Micromonospora described herein.
  • the appropriate dosages of the macrolides will vary depending on the nature of the condition to be treated, but in general however satisfactory results are obtained on administration orally at dosages on the order of from 0.05 to lOmg/kg/day, preferably 0.1 to 7.5 mg/kg/day, more preferably 0.1 to 2 mg/kg/day, administered once or, in divided doses, 2 to 4 times per day.
  • dosages on the order of from 0.01 to 5 mg/kg/day, preferably 0.05 to 1.0 mg/kg/day and more preferably 0.1 to 1.0 mg/kg day can be used.
  • Suitable daily dosages for patients are thus on the order of from 2.5 to 500 mg p.o., preferably 5 to 250 mg p.o., more preferably 5 to 100 mg p.o., or on the order of from 0.5 to 250 mg i.v., preferably 2.5 to 125 mg i.v. and more preferably 2.5 to 50 mg i.v..
  • Dosaging may also be arranged in a patient specific manner to provide pre-determined trough blood levels, as determined by the RIA technique.
  • patient dosaging may be adjusted to achieve regular on-going trough blood levels, as measured by RIA, on the order of from 50 to 1000 ng/ml, preferably 150 to 500 ng/ml; analogously to methods of dosaging currently employed for Ciclosporin immunosuppressive therapy.
  • the Macrolides may be administered by any conventional route, in particular enterally, parenterally, or topically.
  • Suitable enterally administered forms are solutions for drinking, tablets or capsules.
  • Suitable parenteral forms are injectable solutions or suspensions.
  • Suitable unit dosage forms for oral administration may comprise from 1 to 50 mg of the Macrolides; usually 1 to 10 mg.
  • Pharmaceutical compositions for topical administration include ointments or creams, e.g., containing 0.1-10%, preferably about 1-2% of Macrolide together with a topical earner or in a topical formulation.
  • the invention provides for Macrolides to be used as a screening tool to determine the presence of macrophilin-binding immunosuppressants in broths. This can be done using standard competitive assays based on the FK506 antagonistic properties of the Macrolide.
  • a Macrolide is immobilized in microtiter wells and then allowed to bind in the presence of a test broth to labelled macrophilin- 12.
  • Micromonospora sp.A92-306401 was deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Mascheroder Weg lb, D-3300 Braunschweig, Germany on July 30, 1993 under the terms of the Budapest Treaty, and has been assigned the accession number DSM 8429.
  • the strain DSM 8429 can be assigned to the genus Micromonospora as a novel species, designated A92-306401, using standard classification systems, e.g., as described in Bergey's Manual (1989) and The Prokaryotes (1992).
  • the cell walls of this microorganism contain meso-diaminopimelic acid.
  • the fatty acids are iso- and anteiso-branched straight and unsaturated and characteristically 18:0 (stearic acid).
  • the sugar spectrum is composed of ribose, arabinose, xylose, mannose, galactose, glucose , meso-inositol and an unknown sugar which is not madurose (retention time 16.5 using the method of Saddler et al.)
  • the mycelium is formed of thin hyphae and does not break down in fragments. No aerial mycelium is formed on the traditionally used media. Spores are in most of the cases rare, non-motile and singular.
  • the strain grows on various organic and inorganic media.
  • the substrate mycelium grows as hyphae and is generally orange to salmon.
  • the ability of A92-306401 to grow on usual biological media, its carbon utilization, and its physiological characteristics are presenting in the following tables.
  • yeast extract/ growth good malt agar substrate mycelium: orange-ocher soluble pigment: none
  • oatmeal growth good substrate mycelium: dark ocher soluble pigment: none
  • glucose-asparagine growth good substrate mycelium: salmon soluble pigment: none
  • Inorganic salts/ growth spare starch agar substrate mycelium: ocher soluble pigment: none
  • Sucrose/ growth sparse nitrate agar substrate mycelium: weak salmon soluble pigment: none
  • Glycerol/ growth good asparagine agar substrate mycelium: orange soluble pigment: none
  • nitrate reduction positive but limited starch hydrolysis: negative tyrosine degradation: positive but limited milk peptonization: positive melanin formation: negative on peptone-yeast-iron-agar; positive on tyrosine agar gelatine liquefaction: negative growth temperatures: 13-37°c. No growth at 45°C. ⁇ ily sparse at 13°C. pH-range: 5 to 9, but onl ⁇ sparse growth at pH 5
  • NaCl resistance up to 2%.
  • the strain A92-396401 can be mutated or modified into different forms by conventional techniques, e.g., by UV radiation or by treatment with a chemical mutagen such as N-methyl-N'-nitro-nitrosoguanidine.
  • Recombinant clones can be obtained by protoplast fusion. It is intended that all such mutants or recombinants or modified forms, capable of producing the Macrolides and related compounds in a quantity at least as great as described in the example be within the scope of this application.
  • the producing strain may be cultured at suitable temperatures on various culture media using appropriate nutrients and mineral substances, as aerobic or immersion cultures.
  • the fermentation media should contain a utilizable source of carbon, sources of nitrogen and mineral salts including trace elements, all of which can be added in the form of well defined products or as complex mixtures, as are found in biological products of various origins.
  • Agar slant cultures of the strain DSM 8429 are grown for 10 to 14 days at 27°C on the following agar medium:
  • the medium is adjusted to pH 6.6-6.8 with NaOH/H 2 SO 4 , then sterilized for 20 min. at 121°C.
  • the cultures can be stored at -25°-70°C.
  • Suspension in glycerol-peptone can be stored under liquid nitrogen.
  • Soya protein (Siber Hegner) 2.50g
  • the medium is adjusted to pH 6.8-7.2 with NaOH/H 2 SO 4 and sterilized for 20m at 121°C.
  • composition of the trace element solution A is as follows:
  • the precultures are fermented for 96 hr. at 27 °c on a rotary shaker at 200 rpm with an eccentricity of 50mm.
  • One 60 liter bioreactor containing 50 liters of preculture medium is inoculated with 5 liters of the preculture and fermented for 72 hr. at 27°C.
  • the fermenter is rotated at 150 rpm. during the first 48 hours and thereafter at 200 rpm.
  • Air is introduced at a rate of 0.5 liter per minute per liter medium.
  • One 600 liter fermentation vessel containing 500 liters of the main culture medium is inoculated with 50 liters of intermediate culture.
  • the composition of the main culture medium is as follows:
  • the pH is adjusted to 6.5 with KOH/H 2 SO 4 .
  • the medium is sterilized for 20 min at 121 °C.
  • the main culture is incubated for five days at 24°C.
  • the fermentation vessel is rotated at 60 rpm during the 24 first hours and herafter at 80 rpm. Air is introduced at 0.5 liter per minute per liter medium during the 24 first hours and thereafter at 0.8 liter per minute per liter medium.
  • the whole broth of a 700 liter fermentation is stirred twice for 2 hours with 700 liters of ethyl acetate in a Dispax apparatus and thereafter the two phases are separated in a separator.
  • the combined ethyl acetate phases are evaporated to dryness under reduced pressure.
  • the crude extract is then defatted by separation with 3x 101 of methanol/water 9:1 and 3x 101 of hexane.
  • the methanol/water phases are combined and the methanol is distilled off under reduced pressure.
  • the residue is extracted twice with 5 liter ethyl acetate. Evaporation to dryness under reduced pressure gives ca. 250 g defatted extract.
  • the extract is dissolved in 1 liter of ethyl acetate and 600 g of silica gel are added and evaporated to dryness under reduced pressure in a rotary evaporator.
  • This impregnated silica gel is added to a column of 1 kg silica gel and the components of the extract are separated by chromatography using methyl-tertiary -butyl-ether (MTBE)/hexane 1 :1 as eluent.
  • MTBE methyl-tertiary -butyl-ether
  • the polarity of the eluent is increased by using MTBE/hexane 3:1, MTBE, MTBE + 5% methanol, MTBE+ 10% methanol and methanol.
  • Fractions of 2 liters are collected and analyzed by HPLC and MBA (macrophilin binding assay). Fractions 3 through 11 showing good MBA activity are combined and kept in 500 ml methanol solution. A precipitate of inactive material is formed which is removed by filtration. The filtrate is added to a column of 1 kg Sephadex LH20 and chromatography is started collecting fractions of 800 ml. Fractions 3 and 4 are taken together and again chromatographed on a column of 1.25 kg Sephadex LH20 in methanol solution. Active fractions 2 to 6 from this separation are taken for further chromatographic separation on a column of 3 kg Lichroprep RP18 (Merck) in methanol water 8:2.
  • Fractions 3 and 5 are the most active ones in the MBA test showing that more than one compound is responsible for the biological activity.
  • Fraction 3 is again chromatographed on a 3 kg column filled with Lichroprep RP18 in methanol/water 8:2.
  • Fractions 3 to 6 from this run are dissolved in 1 ml methanol to give crystals of macrolide Compound C.
  • the mother liquor is further separated on 20 g silica gel with methylenchloride/methanol/water 92:7.5:0.5. With the aid of HPLC, crystals of pure macrolide Compound D can be collected.
  • fractions 8 to 11 of the reversed phase chromatography are dissolved in 5 ml methanol, resulting in crystallization of Compound A.
  • Fraction 5 is taken for another chromatography run on 3 kg Lichroprep RP18 with methanol/water 8:2.
  • HPLC analysis reveals that fraction 6 and 7 comprise compound B.
  • the ICAM-1 cell Elisa used to determine inhibition of ICAM-1 expression is substantially as described by Winiski and Foster (1992, J. Invest. Dermatol., 99, 48-52).
  • HaCaT cells a spontaneously-transformed, non-tumorigenic human keratinocyte cell line with highly preserved phenotypic differentiation characteristics of normal keratinocytes (Boukamp et al., 1988 J. Cell Biol. 106.
  • the medium is then washed away and the cell monolayers are fixed with 1% parafomraldehyde.
  • the monolayers are incubated with saturating amounts of primary (mouse anti-ICAM-1 monoclonal) and secondary (goat anti-mouse peroxidase conjugated) antibodies.
  • the subsequent peroxidase reaction uses 3-amino-9-ethylcarbazole (AEC) as substrate and generates an insoluble, colored product, which is easily measured in a standard microtiter plate reader.
  • AEC 3-amino-9-ethylcarbazole
  • the HaCaT monolayers are rinsed with PBS (200 ⁇ L), the PBS is poured off from the plates which are then patted dry on top of a paper towel to remove excess liquid. The bottom surfaces of the microtitre plates are gently wiped with a moist facial tissue and then again with a dry facial tissue and absorbance read at 492nm. Before the monolayers can dry out 0.1 ml of 0.1% crystal violet solution in PBS (passed first through a 0.2 ⁇ m filter) is added to each well.
  • Compounds tested were active in this assay, e.g., Compound B has an IC50 of ca. 5 ⁇ M in this assay.
  • the assay employs non-hazardous, non-radioactive, commercially available reagents. It is based on a 96-well cell Elisa method using the human microvascular endothelial cell line HMEC-1. Cells are pretreated for four hours with the test compounds/broth extracts, stimulated for the next 16-18 hours with a cytokine "cocktail" (TNF ⁇ /INF ⁇ ), then parafomaldehy de-fixed for subsequent evaluation of VCAM-1 or E-selectin expression by an indirect immunoperoxidase staining technique. Cytotoxic effects are determined by counting the relative number of cells (Giemsa nuclear stain) after exposure to the test substances, in comparison to the control wells (solvent and media only). Compounds are scored positive if they exhibit >50% VCAM-1 or E-selectin inhibition with ⁇ 25% cell loss.
  • the VCAM-1 /E-selectin assay utilizes an immortalized (SV-40 virus large T antigen) human microvascular endothelial cell line (HMEC-1; Ades et al., Jrl Invest Dermatol 99: 683-690, 1992).
  • HMEC-1 cells constitutively express low levels of ICAM-1 which are upregulated by inflammatory mediators. However, they only express VCAM-1 or E-selectin following cytokine stimulation. Dose-response and time-course experiments are performed to determine the optimal conditions for inducing VCAM-1 and E-selectin expression.
  • CM Endothelial Cell Basal Medium [EBM; Clonetics] supplemented with 10% FCS, 10 ng/ml
  • 96 well flat-bottom microtiter plates are precoated with bovine fibronectin (FN; Sigma # Fl 141) and then seeded with 2 x 10 4 cells/well in 200 ⁇ l of EBM growth medium and incubated overnight.
  • CM culture medium
  • CM supplemented with 5% FCS instead of 10% the culture medium
  • Each 96-well assay is performed with duplicate wells.
  • the cells are then stimulated by adding 20 ⁇ l of concentrated cytokine solution (1500 U/ml INF ⁇ + 2000 U/ml TNF ⁇ ) and incubated for 16-18 hr at 37° C.
  • the cell monolayer is then washed with 1 % paraformaldehyde in EBM medium, fixed in 2% parafomaldehyde for 15 min at room temperature (RT) and rinsed several times with PBS.
  • the PBS is removed from the cells, and the monolayer is incubated for 30 min in PBS containing 10% normal goat serum (NGS).
  • NGS normal goat serum
  • the NGS solution is replaced with 100 ⁇ l/well of the anti-VCAM or anti-ELAM monoclonal antibody (mAb; 1:500 dilution, both from Genzyme) in PBS containing 5% NGS) and incubated overnight at 4° C.
  • the mAb solution is then removed and the cells rinsed several times with PBS, followed by incubation with PBS containing 10% NGS for 30-60 min at RT.
  • the NGS solution is removed and lOO ⁇ l of horseradish peroxidase-conjugated goat F(Ab') 2 anti-mouse IgG antibody (Tago; 1:500 dilution in PBS containing 5% NGS) is added and the plates incubated for 1 hr at RT.
  • the secondary antibody is then removed and the cells rinsed in PBS, which is then replaced with 150 ⁇ l/well of a freshly-prepared and filtered AEC solution (3-amino-9ethyl-carbazole; Sigma) and the plates incubated for 45-60 min at RT.
  • the peroxidase substrate is removed and the cells rinsed in PBS.
  • AEC absorbance values are read on a microtiter plate reader at 550 nm and corrected for "blank" or reference values at 690 n
  • the cells are destained by replacing the PBS with 95% ethanol for 20 min (two 10 min changes) with control by microscopic evaluation.
  • the cells are then rinsed in distilled water (Aquadest) and the monolayer covered with a 33% Giemsa solution in Aquadest for 5 min at RT.
  • the wells are then washed with Aquadest and air dry for at least 15 min.
  • Microscopic evaluation is used to check that only the nuclei are stained, with essentailly no cytoplasmic staining. Giemsa absorbance values are read on a microtiter plate reader at 550 nm and corrected for "blank" values (rows without cells) at 690 nm.
  • the AEC values for constitutive VCAM-1 or E-selectin expression are essentially equal to those of an isotype-matched control mAb and represent the background stain. In every 96-well plate, the mean constitutive value is subtracted from the mean AEC value for each cytokine-stimulated group (EBM and solvent controls, as well as test substance), resulting in a number which represents inducible VCAM-1 or E-selectin Cell adhesion molecule (CAM) expression (referred to as AEC-CAM).
  • Each AEC-CAM value is then divided by the corresponding mean Giemsa value, resulting in a number which estimates relative levels of VCAM-1 or E-selectin expression for a given cell density, based on the number of nuclei (referred to as AEC: Giemsa ratio).
  • AEC (stimulated) - AEC (unstimulated) AEC-CAM
  • AEC-CAM / Giemsa AEC:Giemsa ratio
  • VCAM-1 or E-selectin IC50 values are determined by comparing the AEC:Giemsa values for a test substance with those of the stimulated control (EBM, solvent). These values are then analyzed relative to the IC50 values for Giemsa alone. Strict criteria determine whether the VCAM or E-selectin inhibition versus cytotoxicity (Giemsa) profile indicates a "real" hit which should be pursued.
  • Compounds of the invention tested e.g., Compound A and B, show inhibition of VCAM expression in this assay with an IC 50 of less than 2 ⁇ M.
  • Compounds of the invention tested in an ELAM expression ELISA using swine endothelial cells were active in suppressing ELAM expression as well;
  • HaCaT cells are cultivated in DMEM (Gibco # 074-02100) supplemented with 2.2 g/1 NaHCO 3 , 0.1 1 g/1 sodium pyruvate, 15 mM Hepes, 5% fetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 ⁇ g/ml), and glutamine (to increase the final concentration by 4 mM).
  • DMEM Gibco # 074-02100
  • FCS fetal calf serum
  • penicillin 100 U/ml
  • streptomycin 100 ⁇ g/ml
  • glutamine glutamine
  • cells are detached by trypsinization, suspended in fresh medium, and seeded into 96-well microtiter plates at a final density of 4000 cells/0.2 ml/well. After 24 hours (day 0) the medium is replaced with fresh medium containing graded concentrations of test compound.
  • the extent of cellular proliferation in comparison to solvent controls is measured by a colorimetric assay that measures relative cell mass using the dye sulforhodamine B (Skehan et al, 1990, J. Natl. Cancer Inst. £2, 1107-1112).
  • the "starting cell number" is determined by measuring the relative cell mass on day 0.
  • a dose-response curve is plotted semi-logarithmically and the concentration required for half-maximal inhibition (IC 50 ) is determined by linear interpolation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des macrolides de formule (I) où R1 est H, alkyle, aryle ou acyle; R2 est H ou -OR5 dans lequel R5 est H, alkyle, aryle ou acyle, R3 est -CH2 ou -CH2CH2; et R4 est H, alkyle, aryle ou acyle; étant entendu qu''alkyle' est de préférence C1-6 alkyle, qu''aryle' est un radical d'hydrocarbure aromatique à un ou deux cycles aromatiques; et qu''acyle' est alkylcarbinyle ou arylcarbonyle. Sont également présentés des préparations, des utilisations pharmaceutiques, et des tests à base desdits macrolides ainsi que leur méthode d'obtention et une nouvelle souche productrice.
PCT/EP1994/002894 1993-09-01 1994-08-31 Macrolides antagonistes des immunosuppresseurs fixant la macrophiline WO1995006649A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76925/94A AU7692594A (en) 1993-09-01 1994-08-31 Macrolides as antagonists of macrophilin binding immunosuppressants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9318144.4 1993-09-01
GB939318144A GB9318144D0 (en) 1993-09-01 1993-09-01 Organic compounds

Publications (1)

Publication Number Publication Date
WO1995006649A1 true WO1995006649A1 (fr) 1995-03-09

Family

ID=10741346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/002894 WO1995006649A1 (fr) 1993-09-01 1994-08-31 Macrolides antagonistes des immunosuppresseurs fixant la macrophiline

Country Status (3)

Country Link
AU (1) AU7692594A (fr)
GB (1) GB9318144D0 (fr)
WO (1) WO1995006649A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002285A1 (fr) * 1995-07-04 1997-01-23 Novartis Ag Macrolides
WO1998007743A1 (fr) * 1996-08-22 1998-02-26 Novartis Ag Macrolides
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
WO2002089796A3 (fr) * 2001-05-09 2003-03-13 Novartis Ag Procedes d'immunomodulation selective
EP1687283A2 (fr) * 2003-11-21 2006-08-09 Dade Behring Inc. Procede et composition servant a determiner fk 506
US7745457B2 (en) 2006-03-07 2010-06-29 Wyeth Llc Meridamycin analogues for the treatment of neurodegenerative disorders
WO2013093493A1 (fr) 2011-12-23 2013-06-27 Biotica Technology Limited Nouvel analogue de rapamycine
WO2018148508A1 (fr) 2017-02-10 2018-08-16 Mount Tam Biotechnologies, Inc. Analogue de rapamycine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187049A2 (fr) * 1984-12-24 1986-07-09 Yamanouchi Pharmaceutical Co. Ltd. Micro-organismes micromonospora et leur production d'antibiotiques macrolides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187049A2 (fr) * 1984-12-24 1986-07-09 Yamanouchi Pharmaceutical Co. Ltd. Micro-organismes micromonospora et leur production d'antibiotiques macrolides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G.D. VAN DUYNE ET AL.: "Atomic structure of the rapamycin human immunophilin FKBP-12 complex", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 113, 1991, WASHINGTON, DC US, pages 7433 - 7434 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002285A1 (fr) * 1995-07-04 1997-01-23 Novartis Ag Macrolides
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
WO1998007743A1 (fr) * 1996-08-22 1998-02-26 Novartis Ag Macrolides
WO2002089796A3 (fr) * 2001-05-09 2003-03-13 Novartis Ag Procedes d'immunomodulation selective
EP1687283A2 (fr) * 2003-11-21 2006-08-09 Dade Behring Inc. Procede et composition servant a determiner fk 506
JP2007512340A (ja) * 2003-11-21 2007-05-17 デイド・ベーリング・インコーポレイテッド Ｆｋ５０６の測定に有用な方法及び組成物
EP1687283A4 (fr) * 2003-11-21 2008-09-24 Siemens Healthcare Diagnostics Procede et composition servant a determiner fk 506
US7745457B2 (en) 2006-03-07 2010-06-29 Wyeth Llc Meridamycin analogues for the treatment of neurodegenerative disorders
WO2013093493A1 (fr) 2011-12-23 2013-06-27 Biotica Technology Limited Nouvel analogue de rapamycine
WO2018148508A1 (fr) 2017-02-10 2018-08-16 Mount Tam Biotechnologies, Inc. Analogue de rapamycine

Also Published As

Publication number Publication date
AU7692594A (en) 1995-03-22
GB9318144D0 (en) 1993-10-20

Similar Documents

Publication Publication Date Title
KR930010705B1 (ko) Fr-900520 물질의 제조방법
US6124453A (en) Macrolides
EP1751272B1 (fr) Production de tacrolimus (fk-506) au moyen de nouvelles especes de streptomyces
KR19990028724A (ko) 마크롤라이드
WO1994018207A1 (fr) Macrolide similaire a la rapamycine et nouvelle souche de streptomyces produisant celui-ci
WO1995006649A1 (fr) Macrolides antagonistes des immunosuppresseurs fixant la macrophiline
RU2155772C2 (ru) Циклопептолид, штамм гриба, способ получения циклопептолида, терапевтический состав
JPH05123179A (ja) 新規化合物ロイストロダクシン
KR100446323B1 (ko) Ｇｍ-95 물질, 이의 제조 방법 및 용도
WO2009141786A2 (fr) Composés anti-inflammatoires
US5338758A (en) Bicyclic diterpene PAF antagonist compounds
US5789602A (en) Physiologically active substances PF1092A, PF1092B and PF1092C, process for the production thereof, and contraceptives and anticancer drugs containing the same as active ingredients
US5849730A (en) Process for preparing demethylrapamycins
EP0866801B1 (fr) Cyclopeptolides
US8263579B2 (en) Anti-inflammatory compounds
KR960016206B1 (ko) Bu-3862t 항종양 항생제
KR0173195B1 (ko) It-62-b 물질 및 이를 함유하는 의약조성물
KR20040025902A (ko) Ｃｎｓ 장애 치료용 의약의 제조시 티오루틴 디옥사이드및 이의 유도체의 용도 및 이의 제조방법
CA2054232A1 (fr) Les oasomycines, une methode pour les preparer et leur utilisation
HUT71859A (en) Sequiterpenes, their preparation and their use as inhibitors acting on the gaba benzodiazepine receptor
JPH07258263A (ja) 神経細胞分化促進剤およびその製造法
MXPA98000217A (en) Macroli
JP2000125894A (ja) 神経分化促進剤、製造法及び微生物
JPH11116577A (ja) 新規化合物ａｍ６８９８ｅ及びその製法
JP2000226391A (ja) マクロライド化合物、および免疫抑制剤の評価方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ FI GE HU JP KG KP KR KZ LK LT LV MD MG MN NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载